<DOC>
	<DOC>NCT00160498</DOC>
	<brief_summary>A double blind study to examine the safety and efficacy of different dosages of lercanidipine in normal weight and obese patients with hypertension</brief_summary>
	<brief_title>Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lercanidipine</mesh_term>
	<criteria>Body Mass Index (BMI): 18.0 24.9 or 30.0 39.9 kg/m2 (extremes included); Essential hypertension I or II WHO: 140 mmHg ≤ BPs ≤ 179 mmHg and BPd ≤ 109 mmHg at the end of the placebo runin phase; Secondary hypertension; Diabetes mellitus type 1, insulin dependent diabetes mellitus type 2, fasting blood glucose ≥ 160 mg/dl; Subjects keeping to a hypocaloric diet (except special diet for diabetics) to reduce body weight; History or presence of angioneurotic oedema; Subjects developing a hypertensive crisis during washout or placebo runin period;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Lercanidipine, calcium antagonist, hypertension, obesity</keyword>
</DOC>